Sunday, May 19, 2013 Last update: 5:34 AM
Company Tech News as it Breaks
Trade Events
Antares Pharma, Inc.
News articles for Antares Pharma, Inc.:
Thursday, May 9, 2013
- Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare ConferenceAntares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2013 Healthcare ... read more
Wednesday, May 8, 2013
- Antares Pharma Reports First Quarter 2013 Operating and Financial ResultsAntares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the first quarter ended March 31, 2013. Quarter and ... read more
Tuesday, April 16, 2013
- Antares Pharma Announces the Issuance of a New Patent on VIBEX™ Device PlatformAntares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patent number 8,419,686 which relates to the device-injection site contacting interface. The interface design is applicable to ... read more
Wednesday, April 3, 2013
- Antares Pharma Announces First Shipment of Commercial VIBEX™ Auto-Injector Devices to TevaAntares Pharma, Inc. (NASDAQ: ATRS) today announced the first shipment of commercial-ready VIBEX™ auto-injector devices to Teva at the end of the first quarter 2013. This initial order ... read more
Wednesday, March 13, 2013
- Antares Pharma Reports Fourth Quarter and Full Year 2012 Operating and Financial ResultsAntares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2012. ... read more
Wednesday, February 27, 2013
- Antares Pharma Announces FDA Acceptance of New Drug Application for OTREXUP™Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the New Drug Application (NDA) for OTREXUP™, a potential new product for the subcutaneous delivery of methotrexate (MTX) using Medi-Jet™ ... read more
Wednesday, February 20, 2013
- Antares Pharma to Participate in the 2013 RBC Capital Markets’ Healthcare ConferenceAntares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will participate in the RBC Capital Markets’ Healthcare Conference on Wednesday, ... read more
Monday, December 17, 2012
- Antares Pharma Announces Submission of New Drug Application for OTREXUP™Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for OTREXUP™, a combination product ... read more